Gilead pens $1.5B buyout option deal for Pionyr

[cafead]

via As it continues with its small to medium-sized biotech deals, Gilead Sciences has put down $275 million for a 49.9% share in immuno-oncology biotech Pionyr Immunotherapeutics with the option to buy it out completely should it pass muster in early clinical tests.

article source